Abstract
PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 56-61 |
Number of pages | 6 |
Journal | Clinical and Translational Radiation Oncology |
Volume | 21 |
DOIs | |
State | Published - Mar 2020 |
Keywords
- Dose escalation
- Gynecologic cancer
- PARP-inhibitors
- Poly (ADP-ribose) polymerase
- Radiosensitizer
- Radiotherapy
- Talazoparib
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging